Description
AM281 is a potent and selective central cannabinoid (CB
1) receptor antagonist/inverse agonist (K
is = 12 nM and 4,200 nM for CB
1 and CB
2, respectively). Structurally, it is an analog of the CB
1 inverse agonist rimonabant . It has no effect on the vanilloid TRPV1 receptor. AM281 has been used to evaluate the potential effects of compounds at CB
1. It has also been used to study the membrane localization and cycling of CB
1.
Uses
AM 281 acts as a potential CB1 selective receptor cannabinoid antagonist.
Definition
ChEBI: 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-(4-morpholinyl)-3-pyrazolecarboxamide is a member of pyrazoles and a ring assembly.
Biological Activity
Potent, selective CB 1 cannabinoid receptor antagonist/inverse agonist (K i values are 12 and 4200 nM for CB 1 and CB 2 receptors respectively). Increases locomotor activity following systemic administration in vivo . Analog of SR141716A (K i = 14 nM).
References
[1]. lan r, gatley j, lu q, et al. design and synthesis of the cb1 selective cannabinoid antagonist am281: a potential human spect ligand. aaps pharmsci, 1999, 1(2): e4.
[2]. gatley sj, lan r, volkow nd, et al. imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid cb1 receptors in vivo. j neurochem, 1998, 70(1): 417-423.
[3]. vaseghi g, rabbani m, hajhashemi v. the cb(1) receptor antagonist, am281, improves recognition loss induced by naloxone in morphine withdrawal mice. basic clin pharmacol toxicol, 2012, 111(3): 161-165.